Preclinical evidences demonstrate that this approach may be particularly effective, at least in some experimental models in which the combination of EGFR antagonists, such as gefitinib or erlotinib, and mTOR inhibitors, such as rapamycin and everolimus, resulted in an enhanced tumour cell growth control (Gemmill et al, 2005; Goudar et al, 2005; Rao et al, 2005; Wang et al, 2006; Jimeno et al, 2007). Here, MTOR is linked to neoplasm.